F-1/A: NewGenIvf Group Limited Files Amendment No. 4 to Form F-1 Registration Statement

NewGenIvf Group Limited is registering up to 139,425,259 Class A Ordinary Shares for resale by selling shareholders following previous private placements of convertible notes and warrants.

Summary

• NewGenIvf Group Limited, a British Virgin Islands holding company operating assisted reproductive services (ARS) in Asia-Pacific, has filed an amendment to its Form F-1 registration statement.
• The filing concerns the resale of up to 139,425,259 Class A Ordinary Shares by selling shareholders.
• These shares are issuable upon conversion of senior convertible notes and exercise of warrants previously issued in private placements.
• The company will not receive any proceeds from the sale of shares by the selling shareholders, but may receive proceeds from the cash exercise of warrants, which would be used for working capital and general corporate purposes.
• NewGenIvf's Ordinary Shares currently trade on The Nasdaq Global Market under the symbol NIVF, but the company faces potential delisting due to non-compliance with Nasdaq's minimum market value requirements.
• The company's operations are primarily conducted through subsidiaries in Thailand, Cambodia, and Kyrgyzstan, focusing on IVF treatments and surrogacy services.
• NewGenIvf's revenue for the year ended December 31, 2023, was US$5,136,153, with a net income of US$108,418.
• The company is taking steps to address its financial situation, including exploring fundraising projects.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While it highlights the company's growth strategies and market opportunities, it also acknowledges significant risks, including potential delisting from Nasdaq and the company's ability to continue as a going concern. The financial results show a decrease in revenue and net income, further contributing to the cautious sentiment.

Positives

• The selling shareholders are offering their securities to further enhance liquidity in the public trading market for our equity securities in the United States.
• The company is exploring fundraising projects to improve its cash flow position.

Negatives

• The company faces potential delisting from Nasdaq due to non-compliance with minimum market value requirements.
• The company may not be able to continue operating as a going concern.
• The company will not receive proceeds from the resale of shares.

Risks

• The company may not be able to continue operating as a going concern.
• The company faces potential delisting from Nasdaq due to non-compliance with minimum market value requirements.
• The company operates in a competitive market.
• The company has a limited operating history.
• The company's marketing efforts depend on positive references from existing clients.
• The company may experience net losses and may not sustain profitability in the future.
• The company's future revenue may not grow at the rates it historically has, or at all.
• The company's quarterly and annual results may fluctuate significantly.
• The company may not be able to successfully manage its growth.
• The company may fail to adapt and respond effectively to the changing medical landscape.
• The company may fail to retain and motivate members of its management team.
• The company is reliant on revenue from international clients.
• The defects in certain leased property interests and failure to register certain lease agreements may materially and adversely affect NewGenIvfs business, financial condition, results of operations, and prospects.
• The company currently has no insurance coverage for its operations.
• The company may not be successful in adapting to technological developments.
• If its computer systems fail or suffer security breaches, the company may incur a material disruption of its services.
• The company may not be able to comply with the filing deadlines for reports that it files pursuant to the Exchange Act.

Future Outlook

NewGenIvf plans to offer broad fertility services for fertility tourists across Asia Pacific, continue to invest in laboratories and facilities updates, increase its brand awareness and market share, as well as expand service reach through acquisitions and partnerships.

Industry Context

The ARS market in Asia Pacific is growing, driven by factors such as increasing infertility rates, later maternal age, and greater social acceptance of fertility treatments. However, access to treatment is often limited due to financial challenges and other barriers.

Comparison to Industry Standards

• According to CIC, the average cost per IVF cycle in the US is around US$12,000 (excluding medication), which is 65% higher than that of Asia-Pacific market.
• Meanwhile, the average cost per IVF cycle by NewGenIvf is around US$7,000 (excluding medication).

Stakeholder Impact

• Shareholders face potential dilution from the issuance of shares upon conversion of notes and exercise of warrants.
• Shareholders face the risk of delisting from Nasdaq.
• The company's ability to execute its growth strategies and maintain operations is dependent on securing sufficient capital.

Next Steps

• The Selling Shareholders may sell all or a portion of the Ordinary Shares from time to time in market transactions through any market on which our Ordinary Shares are then traded, in negotiated transactions or otherwise, and at prices and on terms that will be determined by the then prevailing market price or at negotiated prices directly or through a broker or brokers, who may act as agent or as principal or by a combination of such methods of sale (see Plan of Distribution).

Key Dates

Keywords

IVF, surrogacy, fertility, NewGenIvf, shares, warrants, Nasdaq, delisting, resale, notes